CureVac Announces Voting Results of Extraordinary General Meeting

^
Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of Extraordinary General Meeting

26.11.2025 / 00:46 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

CureVac Announces Voting Results of Extraordinary General Meeting

TÜBINGEN, Germany / BOSTON, USA - November 25, 2025 - CureVac N.V. (Nasdaq:
CVAC)(CureVac or the Company), a pioneering multinational biotech company
developing a new class of transformative medicines based on messenger RNA
(mRNA), today announced the voting results of its Extraordinary General
Meeting (EGM).

CureVac's shareholders approved all proposals relating to BioNTech SE's
public exchange offer for all outstanding shares in CureVac (Offer) at the
EGM with an approval rate of over 99.16% of the votes cast.

The Offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with
CureVac's shareholders advised to tender their shares by 6:00 pm Eastern
Time on December 2, 2025, due to operational deadlines.

Voting results - Overview

A table containing tabulations of the votes cast is set forth below:

Agenda Item Consummation of post-offer reorganization
3
Agenda Item Conditional resolution to enter into a legal
3.a. merger (juridische fusie) of the Company (as
disappearing company) with and into CureVac
Merger B.V. (as acquiring company surviving such
merger) (New Topco), with New Topco issuing
class A shares in its capital to the Company's
shareholders (other than BioNTech SE (Buyer))
and class B shares in its capital to Buyer, in
accordance with Sections 2:309 et seq. of the
Dutch Civil Code (the Legal Downstream Merger) -
accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
158,646,068 Yes votes 99.-
95%
of
the
va-
lid
vo-
tes
cas-
t
84,255 No votes 0.0-
5%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional resolution to approve, to the extent
3.b. required under applicable law and the Company's
articles of association and bylaws
(reglementen), (i) the Legal Downstream Merger,
(ii) the subsequent sale and transfer of all
outstanding shares in the capital of CureVac SE
by New Topco to Buyer and (iii) the subsequent
cancellation of all outstanding class A shares
in the capital of New Topco - accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
158,639,956 Yes votes 99.-
94%
of
the
va-
lid
vo-
tes
cas-
t
89,164 No votes 0.0-
6%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional release from liability
4
Agenda Item Conditional release of managing directors from
4.a. liability for the exercise of their duties -
accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
157,535,455 Yes votes 99.-
27%
of
the
va-
lid
vo-
tes
cas-
t
1,165,859 No votes 0.7-
3%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional release of supervisory directors
4.b. from liability for the exercise of their duties
- accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
157,485,433 Yes votes 99.-
23%
of
the
va-
lid
vo-
tes
cas-
t
1,219,313 No votes 0.7-
7%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional appointment of Ramón Zapata Gomez as
5 managing director of the Company - accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
157,414,993 Yes votes 99.-
89%
of
the
va-
lid
vo-
tes
cas-
t
171,497 No votes 0.1-
1%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional appointment of supervisory directors
6
Agenda Item Conditional appointment of Sierk Poetting as
6.a. supervisory director of the Company - accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
156,296,489 Yes votes 99.-
18%
of
the
va-
lid
vo-
tes
cas-
t
1,289,511 No votes 0.8-
2%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional appointment of James Ryan as
6.b. supervisory director of the Company - accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
156,260,667 Yes votes 99.-
16%
of
the
va-
lid
vo-
tes
cas-
t
1,327,264 No votes 0.8-
4%
of
the
va-
lid
vo-
tes
cas-
t
Agenda Item Conditional appointment of Annemarie Hanekamp as
6.c. supervisory director of the Company - accepted
158,803,292 Number of shares for which valid votes were cast
(= 70.52% of the registered share capital)
156,257,812 Yes votes 99.-
16%
of
the
va-
lid
vo-
tes
cas-
t
1,327,765 No votes 0.8-
4%
of
the
va-
lid
vo-
tes
cas-
t
About CureVac

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded
in 2000 to advance the field of messenger RNA (mRNA) technology for
application in human medicine. In more than two decades of developing,
optimizing, and manufacturing this versatile biological molecule for medical
purposes, CureVac has introduced and refined key underlying technologies
that were essential to the production of mRNA vaccines against COVID-19, and
is currently laying the groundwork for application of mRNA in new
therapeutic areas of major unmet need. CureVac is leveraging mRNA
technology, combined with advanced omics and computational tools, to design
and develop off-the-shelf and personalized precision immunotherapy
candidates to treat cancer. It also develops programs in prophylactic
vaccines and in treatments that enable the human body to produce its own
therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also
operates sites in the Netherlands, Belgium, Switzerland, and the U.S.
Further information can be found at www.curevac.com.

CureVac Media and Investor Relations Contact

CureVac, Tübingen, Germany

Corporate Communications

communications@curevac.com

Forward-Looking Statements of CureVac

This press release contains statements that constitute "forward looking
statements" as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the
opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,
CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac
Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V.
(the "company") regarding future events or future results, in contrast with
statements that reflect historical facts. Examples include the settlement of
all pending patent disputes in the United States between the company,
Pfizer, and BioNTech relating to mRNA-based COVID-19 vaccines, the Company's
expectations regarding the outcome of pending litigation in other global
jurisdictions, the expected completion of the public exchange offer between
BioNTech and the Company, the discussion of the potential efficacy of the
company's vaccine and treatment candidates and the company's strategies,
financing plans, cash runway expectations, the timing and impact of
restructuring, growth opportunities and market growth. In some cases, you
can identify such forward-looking statements by terminology such as
"anticipate," "intend," "believe," "estimate," "plan," "seek," "project,"
"expect," "may," "will," "would," "could," "potential," "intend," or
"should," the negative of these terms or similar expressions.
Forward-looking statements are based on management's current beliefs and
assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company's
performance, and you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties and
other variable circumstances, including risks related to the proposed
acquisition by BioNTech, negative worldwide economic conditions and ongoing
instability and volatility in the worldwide financial markets, ability to
obtain funding, ability to conduct current and future preclinical studies
and clinical trials, the timing, expense and uncertainty of regulatory
approval, reliance on third parties and collaboration partners, ability to
commercialize products, ability to manufacture any products, ability to
implement our pipeline strategy, possible changes in current and proposed
legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company's industry, the
effects of the COVID-19 pandemic on the company's business and results of
operations, ability to manage growth, ability to implement, maintain and
improve effective internal controls, reliance on key personnel, reliance on
intellectual property protection, ability to provide for patient safety,
fluctuations of operating results due to the effect of exchange rates,
delays in litigation proceedings, the impact of adverse settlements or other
judicial outcomes and other important factors discussed under the caption
"Risk Factors" in the company's annual report on Form 20-F filed with the
U.S. Securities and Exchange Commission (the "SEC") on April 11, 2025, as
such factors may be updated form time to time in its other filings with the
SEC. Such risks and uncertainties may cause the statements to be inaccurate
and readers are cautioned not to place undue reliance on such statements.
Many of these risks are outside of the company's control and could cause its
actual results to differ materially from those it thought would occur. The
forward-looking statements included in this press release are made only as
of the date hereof. The company does not undertake, and specifically
declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments, except as required by law.

For further information, please reference the company's reports and
documents filed with the SEC. You may get these documents by visiting EDGAR
on the SEC website at www.sec.gov.

---------------------------------------------------------------------------

Veröffentlichung einer Mitteilung, übermittelt durch EQS Group.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Originalinhalt anzeigen:
https://eqs-news.com/?origin_id=24ecb771-ca53-11f0-be29-0694d9af22cf&lang=de

---------------------------------------------------------------------------

Sprache: Deutsch
Unternehmen: CureVac
Friedrich-Miescher-Str. 15
72076 Tübingen
Deutschland
EQS News ID: 2235868

Ende der Mitteilung EQS News-Service
---------------------------------------------------------------------------

°